IP Library Granted Patent US 7,250,165
Granted Patent B2
US 7,250,165 · App. 09/920,137 · Granted Jul 31, 2007

Anti-TNF antibodies, compositions, methods and uses

Assignee: Centocor, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,250,165
App. No.
09/920,137
Granted
Jul 31, 2007
Kind
B2
Abstract

The present invention relates to at least one novel anti-TNF antibodies, including isolated nucleic acids that encode at least one anti-TNF antibody, TNF, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Claims (5)

1. An isolated human anti-TNF antibody, comprising at least one variable region, wherein the variable region of the heavy chain comprises SEQ ID NO:7 and the variable region of the light chain comprises SEQ ID NO:8.

2. A TNF antibody according to claim 1 , wherein said antibody binds TNF with an affinity of at least one selected from at least 10 −9 M, at least 10 −10 M, at least 10 −11 M, or at least 10 −12 M.

3. A TNF antibody according to claim 1 , wherein said antibody is a neutralizing antibody.

4. A composition comprising an isolated human anti-TNF antibody, comprising at least one variable region, wherein the variable region of the heavy chain comprises SEQ NO:7 and the variable region of the light chain comprises SEQ ID NO:8, and at least one pharmaceutically acceptable carrier or diluent.

5. A medical device, comprising an isolated human anti-TNF antibody, comprising at least one variable region, wherein the variable region of the heavy chain comprises SEQ ID NO:7 and the variable region of the light chain comprises SEQ ID NO:8, wherein said device is suitable to contacting or administering said anti-TNF antibody by at least one mode selected from parenteral, subcutaneous, intramuscular, or intravenous.

Assignments (3)
MERGER Recorded Oct 3, 2013
From: CENTOCOR, INC.
To: CENTOCOR ORTHO BIOTECH INC.
Reel/Frame 031337/0037 →
CHANGE OF NAME Recorded Oct 3, 2013
From: CENTOCOR ORTHO BIOTECH INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 031337/0196 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2001
From: GILES-KOMAR, JILL; HEAVNER, GEORGE; KNIGHT, DAVID M.; SCALLON, BERNARD; SHEALY, DAVID
To: CENTOCOR, INC.
Reel/Frame 012151/0183 →
Continuity (3)
Provisional Application 6023682600 · Sep 29, 2000
Provisional Application 6022336000 · Aug 7, 2000
Related Publication 20030049725A1 · Mar 13, 2003